As you may already know, nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) – the most common chronic liver disease in the world. NASH is a serious disease that can progress to chronic liver damage such as advanced fibrosis or cirrhosis, liver failure, or liver cancer. Right now, clinical research for NASH is underway, and you may be eligible to participate.
divider
Thank you for considering a clinical trial
Below you will find clinical trials that are either currently recruiting participants (noted as "Recruiting") or starting to recruit participants (noted as "Not Yet Recruiting").
Here are some options for you to find more information:
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
View Trial Details
A NASH diagnosis is characterized by NAFLD with steatosis (retaining excess fatty tissue), liver cell injury, liver cell death, and inflammation. Other symptoms include:
In most cases, NASH is the consequence of a diet high in fat and sugar, and a lack of physical activity. With lifestyle changes – like healthier eating and exercise – the liver can actually begin to repair itself. But if you’ve recently been diagnosed with NASH, it can be hard to know what steps to take.
For additional information and support regarding NASH, please visit one of the following advocacy sites:
divider
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
